Mainz Biomed Expands Commercial Footprint into Poland
Total addressable market in Poland is estimated at 21 million patients BERKELEY, US – MAINZ, Germany – May 31, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp. z […]
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöller-Kipper
Employees found the online patient portal, through which they ordered the ColoAlert® test, easy-to-use and convenient BERKELEY, US – MAINZ, Germany – May 24, 2023 —Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today initial results from its colorectal cancer (CRC) screening […]
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
ColoAlert® Revenue Increases 152% Year Over Year BERKELEY, US – MAINZ, Germany – May 16, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today first quarter results which ended March 31, 2023 and provided a corporate update. Key Highlights […]
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
Combination of DNA biomarkers with microbiome biomarkers has potential to enhance technical profile of novel pancreatic cancer screening test Joint research project to discover disease specific microbiome biomarkers BERKELEY, Calif. and MAINZ, Germany, May 10, 2023 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in […]
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany. BERKELEY, US – MAINZ, Germany – [May 3, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has added Eurofins GeLaMed to its network of lab partners […]
Mainz Biomed to Participate in Digestive Disease Week 2023
Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery BERKELEY, US – MAINZ, Germany – May 1, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the annual Digestive Disease […]
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
BERKELEY, US – MAINZ, Germany – April 27, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activities in May: Commencement of Voluntary Quarterly Reporting: Under the disclosure requirements of the U.S. NASDAQ listing, foreign issuers are required to […]
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients. BERKELEY, US – MAINZ, Germany – [April 26, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de […]
Mainz Biomed Provides Full Year 2022 Financial Results
ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, US – MAINZ, Germany – April 10, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended […]
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
BERKELEY, US – MAINZ, Germany – [April 4, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies, have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate […]
